title: Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled-release matrix system of high load and highly water-soluble drug niacin.
abstract: Novel, controlled-release formulations for high drug load, highly water soluble compound niacin based on polyethylene oxide (PEO) and hydroxypropylmethyl cellulose (HPMC) matrices were developed and investigated. The effect of sodium bicarbonate as a modulator of swelling, erosion, and drug release and its impact on changes in the kinetics of axial swelling and gel strength were evaluated by textural analysis during dissolution study. The drug release rate from PEO-based matrices was faster and correlated with lower gel strength, greater water uptake, and greater matrix erosion. Slower release rate and greater release duration correlated significantly with greater matrix swelling with negligible matrix erosion for the HPMC-based matrix system. Inclusion of sodium bicarbonate in the polymeric matrix salted out the macromolecules and increased gel strength and gel viscosity, especially in the vicinity of the swelling fronts. An in vivo study in human subjects after administration of the formulations and a commercial product exhibited similar plasma concentrations. For the formulation of interest, the mean drug fraction absorbed by the body was calculated by the Wagner-Nelson technique, and a level A "in vitro-in vivo correlation" was observed between the percent released in vitro and percent absorbed in vivo. The developed formulations appear to be robust and easy to manufacture with maximum flexibility with respect to drug dose, polymeric carriers, duration, and kinetics of drug release.
authors.affiliation: Product Development, SCOLR Pharma, Inc., Bellevue, Washington, USA.
authors.forename: S
authors.initials: S
authors.lastname: Turner
authors.forename: C
authors.initials: C
authors.lastname: Federici
authors.forename: M
authors.initials: M
authors.lastname: Hite
authors.forename: R
authors.initials: R
authors.lastname: Fassihi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D065347:Hypromellose Derivatives; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008747:Methylcellulose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D009525:Niacin / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry; D010539:Permeability / Q000187:drug effects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D017693:Sodium Bicarbonate / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D012995:Solubility / Q000187:drug effects*; D013270:Stomach / Q000187:drug effects; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods*; D013810:Therapeutic Equivalency; D014867:Water / Q000378:metabolism
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D013607:Tablets; D014867:Water; D009525:Niacin; D065347:Hypromellose Derivatives; D011092:Polyethylene Glycols; D017693:Sodium Bicarbonate; D008747:Methylcellulose